Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Retained Earnings (2021 - 2025)

Historic Retained Earnings for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to -$476.3 million.

  • Kiniksa Pharmaceuticals International's Retained Earnings rose 701.17% to -$476.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$476.3 million, marking a year-over-year increase of 701.17%. This contributed to the annual value of -$521.1 million for FY2024, which is 903.71% down from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Retained Earnings stood at -$476.3 million, which was up 701.17% from -$494.8 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Retained Earnings registered a high of -$476.3 million during Q3 2025, and its lowest value of -$720.6 million during Q2 2022.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Retained Earnings had a median value of -$504.3 million in 2023 and averaged -$546.7 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Retained Earnings crashed by 2357.32% in 2022 and then surged by 3209.27% in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Retained Earnings stood at -$675.4 million in 2021, then rose by 27.15% to -$492.0 million in 2022, then rose by 2.86% to -$478.0 million in 2023, then dropped by 9.04% to -$521.1 million in 2024, then grew by 8.6% to -$476.3 million in 2025.
  • Its Retained Earnings stands at -$476.3 million for Q3 2025, versus -$494.8 million for Q2 2025 and -$512.6 million for Q1 2025.